The indicative issue price has been set at ₹755 per share, implying a 3.04% discount to the last closing price of ₹778.65 on NSE (16 June, 2026) and a 2.17% discount to the SEBI floor price of ₹771.73 per share. The issue size is based on an exchange rate of US$ 1 = ₹94.6992, with up to 19,867,549 equity shares proposed to be issued, resulting in a dilution of 4.73% of pre-issue equity share capital of 400,138,935 shares.
The SEBI floor price has been fixed at ₹771.73 per equity share, as per applicable ICDR regulations.
The issue proceeds are proposed to be utilised towards repayment and/or prepayment of certain outstanding borrowings of the company, investments into subsidiaries including Chalasani Hospitals Private Limited, KIMS Hospitals Private Limited and KIMS Hospital Bengaluru Private Limited for repayment of their borrowings, and general corporate purposes.
The transaction is being managed by IIFL Capital and Jefferies India Private Limited as book running lead managers, with listing proposed on NSE and BSE. The deal was launched on 16 June, 2026 (post market close), with pricing expected on or around 19 June, 2026 and listing anticipated on or around 25 June, 2026.
The trading window for designated persons under the insider trading code has been closed from 16 June, 2026 until 48 hours after determination of the issue price.
Krishna Institute of Medical Sciences Limited shares ended at ₹779.90 on NSE, up ₹10.05 or 1.31% as on 16 June 2026.
